He pointed to a study in which one-fifth of patients with newly diagnosed follicular lymphoma who went with a watch-and-wait approach had at least one GELF criteria, while more than one-third who ...

The U.S. Food and Drug Administration has approved Monjuvi (tafasitamab-cxix) for the treatment of adult patients with relapsed or refractory follicular lymphoma.

Patients with relapsed/refractory (R/R) follicular lymphoma reported consistent or increased response rates, survival benefits, and health-related quality of life (HRQOL) when taking epcoritamab ...

This discrepancy might be attributed to the fact that the Korean study identified NBNR primarily in follicular-variant papillary thyroid carcinoma rather than classical papillary thyroid carcinoma.

Background/aims To describe in vivo confocal microscopy (IVCM) features of microsporidial keratoconjunctivitis in immunocompetent adult patients. Methods Patients suspected clinically to be suffering ...

Follicular lymphoma is an indolent malignancy with a generally favorable prognosis, with survival often measured in decades. Yet up to 20% of patients develop early progression after starting ...

Discover the main types of pink eye, their symptoms, treatments, and prevention tips for both children and adults in this comprehensive guide to conjunctivitis.

As a lymphoma survivor, I struggle with the positivity trap — sometimes, I just want my fears validated instead of being reassured everything is fine.

The follicular phase can have a big impact on mood and hormones. Here, an ob-gyn breaks down the follicular phase, including common signs and symptoms.

Monjuvi plus Revlimid and Rituxan demonstrated improved progression-free survival for patients with relapsed or refractory follicular lymphoma.

Incyte’s previously disclosed phase 3 win in relapsed or refractory follicular lymphoma (R/R FL) sent the company racing to file an expansion bid for its Monjuvi (tafasitamab) by year-end.

Further, follicular conjunctivitis was the most prevalent allergy type in the concurrent group (61.1%) vs. papillary conjunctivitis in the non-concurrent group (66.7%).